| 产品名称： | SH3 |
|---|---|
| 商品货号： | TS210937 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain: CB6F1/J (B cell); BALB/c (myeloma) |
| Applications： | The antibody reacts with mesenchymal stem cells from bone marrow and some tissues of mesenchymal origin. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human mesenchymal stem cells |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human mesenchymal stem cells |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/c mice |
| Comments： | Animals were immunized with human mesenchymal stem cells. Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. The antibody reacts with mesenchymal stem cells from bone marrow and some tissues of mesenchymal origin. |
| Complete Growth Medium： | Modified Dulbeccos medium, 85%; fetal bovine serum, 15%
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 2 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG2b |
| Name of Depositor： | Osiris Therapeutics, Inc. |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Caplan AI, Haynesworth SE. Human mesenchymal stem cells. US Patent 5,486,359 dated Jan 23 1996 Haynesworth SE, et al. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 13: 69-80, 1992. PubMed: 1316137 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | SH3 |
|---|---|
| 商品货号： | TS210937 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain: CB6F1/J (B cell); BALB/c (myeloma) |
| Applications： | The antibody reacts with mesenchymal stem cells from bone marrow and some tissues of mesenchymal origin. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human mesenchymal stem cells |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human mesenchymal stem cells |
| Tumorigenic： | Yes |
| Effects： | Yes, forms ascites in pristane primed BALB/c mice |
| Comments： | Animals were immunized with human mesenchymal stem cells. Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells. The antibody reacts with mesenchymal stem cells from bone marrow and some tissues of mesenchymal origin. |
| Complete Growth Medium： | Modified Dulbeccos medium, 85%; fetal bovine serum, 15%
|
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 2 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG2b |
| Name of Depositor： | Osiris Therapeutics, Inc. |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Caplan AI, Haynesworth SE. Human mesenchymal stem cells. US Patent 5,486,359 dated Jan 23 1996 Haynesworth SE, et al. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 13: 69-80, 1992. PubMed: 1316137 |
